165 related articles for article (PubMed ID: 22714745)
1. A retrospective analysis of voriconazole pharmacokinetics in Japanese pediatric and adolescent patients.
Mori M; Fukushima K; Miharu M; Goto H; Yoshida M; Shoji S
J Infect Chemother; 2013 Feb; 19(1):174-9. PubMed ID: 22714745
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.
Pieper S; Kolve H; Gumbinger HG; Goletz G; Würthwein G; Groll AH
J Antimicrob Chemother; 2012 Nov; 67(11):2717-24. PubMed ID: 22796890
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
4. Oral voriconazole dose in children: one size does not fit all.
Goutelle S; Larcher R; Padoin C; Mialou V; Bleyzac N
Clin Infect Dis; 2010 Oct; 51(7):870; author reply 871. PubMed ID: 20809842
[No Abstract] [Full Text] [Related]
5. Pharmacokinetic/pharmacodynamic profile of voriconazole.
Theuretzbacher U; Ihle F; Derendorf H
Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets.
Dodds Ashley ES; Zaas AK; Fang AF; Damle B; Perfect JR
Antimicrob Agents Chemother; 2007 Mar; 51(3):877-80. PubMed ID: 17145785
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
Gerin M; Mahlaoui N; Elie C; Lanternier F; Bougnoux ME; Blanche S; Lortholary O; Jullien V
Ther Drug Monit; 2011 Aug; 33(4):464-6. PubMed ID: 21743382
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole pharmacokinetics and pharmacodynamics in children.
Neely M; Rushing T; Kovacs A; Jelliffe R; Hoffman J
Clin Infect Dis; 2010 Jan; 50(1):27-36. PubMed ID: 19951112
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.
Michael C; Bierbach U; Frenzel K; Lange T; Basara N; Niederwieser D; Mauz-Körholz C; Preiss R
Antimicrob Agents Chemother; 2010 Aug; 54(8):3225-32. PubMed ID: 20547816
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole pharmacokinetics and photosensitivity in children with cystic fibrosis.
Markantonis SL; Katelari A; Pappa E; Doudounakis S
J Cyst Fibros; 2012 May; 11(3):246-52. PubMed ID: 22284963
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
Purkins L; Wood N; Greenhalgh K; Eve MD; Oliver SD; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):2-9. PubMed ID: 14616407
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
13. Impact of therapeutic drug monitoring of voriconazole in a pediatric population.
Brüggemann RJ; van der Linden JW; Verweij PE; Burger DM; Warris A
Pediatr Infect Dis J; 2011 Jun; 30(6):533-4. PubMed ID: 21127454
[TBL] [Abstract][Full Text] [Related]
14. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
[TBL] [Abstract][Full Text] [Related]
15. Steady-state pharmacokinetics and metabolism of voriconazole in patients.
Geist MJ; Egerer G; Burhenne J; Riedel KD; Weiss J; Mikus G
J Antimicrob Chemother; 2013 Nov; 68(11):2592-9. PubMed ID: 23766489
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.
Purkins L; Wood N; Greenhalgh K; Allen MJ; Oliver SD
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):10-6. PubMed ID: 14616408
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of oral voriconazole in patients with cystic fibrosis.
Clifton IJ; Whitaker P; Metcalfe R; Phillip M; Shaw N; Conway SP; Peckham DG
J Antimicrob Chemother; 2011 Oct; 66(10):2438-40. PubMed ID: 21791443
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics of voriconazole after single dose intravenous and oral administration to alpacas.
Chan HM; Duran SH; Walz PH; Ravis WR
J Vet Pharmacol Ther; 2009 Jun; 32(3):235-40. PubMed ID: 19646087
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.
Doby EH; Benjamin DK; Blaschke AJ; Ward RM; Pavia AT; Martin PL; Driscoll TA; Cohen-Wolkowiez M; Moran C
Pediatr Infect Dis J; 2012 Jun; 31(6):632-5. PubMed ID: 22301479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
